NUCRYST Pharmaceuticals to Release Second Quarter 2008 Financial Results on Tuesday,...

* Reuters is not responsible for the content in this press release.

Tue Aug 5, 2008 2:33pm EDT 

NUCRYST Pharmaceuticals to Release Second Quarter 2008 Financial Results on
Tuesday, August 12, 2008

WAKEFIELD, MA, Aug. 5 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals Corp.
(NASDAQ: NCST; TSX: NCS), a developer and manufacturer of medical products
that fight infection and inflammation, announced plans to release its
financial results for the second quarter 2008 on Tuesday, August 12, 2008.
The company will host a conference call at 9:00 AM ET on Wednesday, August 13,
2008 to discuss the financial results for the quarter.

    Conference call details:

    Date:        Wednesday, August 13, 2008
    Time:        9:00 AM ET
    Dial-in:     877-419-6593 (U.S.)
                 719-325-4916 (International)
    Web cast:    http://www.nucryst.com (Investor Relations section)

    An audio replay of the call will be available for seven days:
    Access:      888-203-1112 (U.S.)
                 719-457-0820 (International)
                 Replay Passcode: 9742016


In addition to the standard disclosure over wire services, a news release and
financial statements will be posted on the NUCRYST website.

About NUCRYST Pharmaceuticals

NUCRYST Pharmaceuticals (NASDAQ: NCST; TSX: NCS) develops, manufactures and
commercializes medical products that fight infection and inflammation using
SILCRYST(TM), its patented atomically disordered nanocrystalline silver
technology. NUCRYST licensed world-wide rights for SILCRYST(TM) wound care
coating products to Smith & Nephew plc, which markets these products in over
30 countries under their Acticoat(TM) trademark. NUCRYST is also developing
pharmaceutical products to address medical conditions that are characterized
by pain, infection and inflammation. The Company has developed its proprietary
nanocrystalline silver in a powder form, referred to as NPI 32101 for use in
medical devices and as an active pharmaceutical ingredient.

Acticoat(TM) is a trademark of Smith & Nephew plc
SILCRYST(TM) is a trademark of NUCRYST Pharmaceuticals Corp.

SOURCE  NUCRYST Pharmaceuticals Corp.

David B. Holtz, Vice President and Chief Financial Officer, NUCRYST
Pharmaceuticals, (781) 224-1444, info@nucryst.com; Gregory W. Gin, Lazar
Partners, (212) 867-1762
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.